Dr Reddy's gets FDA warning letter for three drug plants
Mumbai: Dr Reddy's Laboratories Ltd, India's second-largest drugmaker by sales, received a warning letter from the U.S. Food and Drug Administration over inadequate quality control procedures at three manufacturing plants in India.Dr Reddy's shares fell as much as 12 percent in early trade to their lowest level since July 30.The warning letter was issued by the FDA to Dr Reddy's on Thursday...
Login or Register to read the full article
Mumbai: Dr Reddy's Laboratories Ltd, India's second-largest drugmaker by sales, received a warning letter from the U.S. Food and Drug Administration over inadequate quality control procedures at three manufacturing plants in India.
Dr Reddy's shares fell as much as 12 percent in early trade to their lowest level since July 30.
The warning letter was issued by the FDA to Dr Reddy's on Thursday for its Srikakulam, Miryalaguda and Duvvada drug manufacturing plants - all based in southern India.
The letter followed FDA inspections of these sites in November, January and February, and the company will respond to the agency in 15 days, Dr Reddy's said in a statement on Friday.
"We will continue to actively engage with the agency to resolve these issues," Dr Reddy's Chief Executive GV Prasad said in a statement.
(Reporting by Zeba Siddiqui in Mumbai; Editing by Anand Basu)
Dr Reddy's shares fell as much as 12 percent in early trade to their lowest level since July 30.
The warning letter was issued by the FDA to Dr Reddy's on Thursday for its Srikakulam, Miryalaguda and Duvvada drug manufacturing plants - all based in southern India.
The letter followed FDA inspections of these sites in November, January and February, and the company will respond to the agency in 15 days, Dr Reddy's said in a statement on Friday.
"We will continue to actively engage with the agency to resolve these issues," Dr Reddy's Chief Executive GV Prasad said in a statement.
(Reporting by Zeba Siddiqui in Mumbai; Editing by Anand Basu)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd